Durvalumab vs Sars-Cov-2 Virus Spike Protein

## Durvalumab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Sars-Cov-2 Virus Spike Protein**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Sars-Cov-2 Virus Spike Protein — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Sars-Cov-2 Virus Spike Protein — Vaccine component.